Congress Materials – American Association for Cancer Research (AACR 2025)
2025 American Association for Cancer Research | Apr 25-30 | Chicago, IL
A Phase 2b Study of Subcutaneous Amivantamab With Lazertinib as First-Line Treatment, or With Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-small Cell Lung Cancer (NSCLC): COPERNICUS
Balazs Halmos, Narjust Florez, Sarah Goldberg, Wade Iams, Xiuning Le, Ticiana Leal, Danny Nguyen, Luis E. Raez, Jonathan W. Riess, Joshua Sabari, David Bjork, Nichelle Stigger, Yichuan Xia, Paul Cifuentes, Denise D’Andrea, Andy L. Johnson, Melissa L. Johnson
AmoyDx Essential NGS Panel (LC 10), One Solution Covering Tumor Tissue and Plasma for Detection of EGFR and cMET Alterations in NSCLC
Min Qing, Jingxun Wu, Yuping Li, Jianmin Li, Xing Li, Cheng Li, Yin Shi, Xuejun Chen, Zhenjun Tan, Xiaofang Zhuo, Chengjuan Xiong, Longen Zhou, Flora Berisha, Changbin Zhu
Discovery of WRN helicase inhibitors that covalently engage a novel, induced allosteric site
Francis W. Hunter, Lindsey DeRatt, Kenneth Maksimchuk, Tatsuya Maehigashi, Seong Joo Koo, Liesbeth Micholt, Ranjeet P. Dash, Faraz Kazmi, Zhengyu Jiang, Albi Francis, Neetu Shukla, Aaron Patrick, Trpta Bains, Romy Perez-Abraham, Nikit Kumar, Zhijie Liu, Brian Reiss, Caitlin Morgan, Inha Heo, Werner Eyckmans, Gerald Chu, Anna Kuhn, Lorraine Angelillo, Lin-Chien Huang, Yu Sun, Ashley M. Rouleau, Yongkang Kim, John J. H. Shin, Harris Bell-Temin, Victoria Wong, Ruth Steele, Paul Shaffer, Kurtis E. Bachman, David Pocalyko, Scott Kuduk
Establishing Optimal Care Coordination in Localized Bladder Cancer in the United States: A Modified Delphi Consensus Study
Gautam Jayram, Monica Baskin, Gordon Brown, Mollie Deshazo, Michael Fabrizio, Hiremagalur Balaji, Angela Hunter, Mukul Singhal, Arveen Kaur, Mike Lattanzi, Lynn Redmond, Guru Sonpavde
Extending ENPP3 expression inference from tissue microarrays to whole tissue sections: building a case for automated patient enrichment and IHC scoring
Erik Ames Burlingame, Fatemeh Koochaki, Tsun-Wen Sheena Yao, Shajo Kunnath- Velayudhan, Chaitanya Parmar, Laurie Lenox, Tommaso Mansi, Joel Greshock, Kristopher Standish, Albert Juan Ramon
Geographic and Racial Disparities in Bladder Cancer Care in the U.S.
Atreyee Majumder, Daniel Erim, Arveen Kaur, Lisa Dwyer Orr
Initial results from a Phase 1 study of an A2a receptor antagonist, administered as monotherapy and in combination with anti-PD1 therapy in patients with advanced non-small cell lung cancer
Prantesh Jain, Alex Spira, Se-hoon Lee, Byoung Chul Cho, Enriqueta Felip, Andres Aguilar, Sarah Gordon, Sebastian Ochsenreither, Thomas Wehler, Amanda McGillivray, Ariel Chen, Raja Venkatasubramanian, Rajesh Bandekar, Rosa Martín-Pérez, Shu Jin, Aisha Hasan, and Brian S. Henick
Mechanisms of Acquired Resistance and ctDNA Clearance in EGFR-Mutated Advanced NSCLC Following Lazertinib Treatment: Results From the Phase 3 LASER301 Study
Byoung Chul Cho, Ki Hyeong Lee, Chin Heng Fong, Anastasia Zimina, Yong Kek Pang, Sergey Orlov, Joo-Hang Kim, Jason K Sa, YuKyung Kim, Mi-Jung Kwon, SeokYoung Choi, Dongmin Kim, Min Kim, Myung-Ju Ahn
PRMT5 as a target in CRC interception: synthetic lethal dependency identified in APC-LOF preclinical models of FAP disease
Dana Gaffney, Fabian Hulpia, Jan Willem Thuring, Eileen Vesely, Edward Retzbach, Zienab Etwebi, Zhengyu Jiang, Albi Francis, Bethany Mattson, Victoria Wong, Glenn S. Cowley, Mariana Silva, Gerben ten Hag, Rene Overmeer, Carla Verissimo, Sylvia F Boj, Johan Nicolaï, Mark Hixon, Gerry Chu, Andrea Disandro, Kathleen W. Clancy, Alexandra Liddane, Kurtis E. Bachman, David Pocalyko
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.